Cargando…

Reply to: “Association of chronic liver disease with the prognosis of COVID-19 patients”

Detalles Bibliográficos
Autores principales:	Mallet, Vincent, Schwarzinger, Michaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Association for the Study of the Liver. Published by Elsevier B.V. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486584/ https://www.ncbi.nlm.nih.gov/pubmed/34606914 http://dx.doi.org/10.1016/j.jhep.2021.09.022

Ejemplares similares

Reply to: “Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: A case control study from the prospective COVID-ICU database”
por: Depret, François, et al.
Publicado: (2022)

Association of chronic liver disease with the prognosis of COVID-19 patients
por: Long, Junyu, et al.
Publicado: (2022)

Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered”
por: Mallet, Vincent
Publicado: (2021)

Reply to “Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19”
por: Khan, Md. Saiful Islam, et al.
Publicado: (2021)

Reply to: Comments on “Association of liver abnormalities with in-hospital mortality in patients with COVID-19”
por: Ding, Ze-yang, et al.
Publicado: (2021)

Reply to: “COVID-19-associated liver injury (COVALI): role of hepatologists”
por: Li, Dongxiao, et al.
Publicado: (2021)

Reply to: “Clinical characteristics of COVID-19 patients with abnormal liver tests”
por: Cai, Qingxian, et al.
Publicado: (2020)

'Post-COVID-19 chronic symptoms' – Author's reply
por: Davido, Benjamin, et al.
Publicado: (2021)

Reply to: “Liver tests abnormalities in COVID-19: trick or treat?”
por: Cai, Qingxian, et al.
Publicado: (2020)

Liver damage associated with Covid-19: A direct causality is difficult to establish
por: Mallet, Maxime, et al.
Publicado: (2021)

Reply to: Association of liver steatosis and fibrosis with clinical outcomes in patients with SARS-CoV-2 infection (COVID-19)
por: López-Mendez, Ivan, et al.
Publicado: (2021)

Reply: Controversies on autoimmunity and prognosis in cancer
por: Whiteside, T L
Publicado: (2006)

Reply to “Novaferon, treatment in COVID-19 patients”
por: Zheng, Fang, et al.
Publicado: (2021)

Reply to the letter concerning Kawasaki disease and Covid-19
por: Loomba, Rohit S., et al.
Publicado: (2020)

In Reply: Hormones and COVID-19
por: Park, Myung S., et al.
Publicado: (2023)

Reply to: “Comment on “Quality of life and unmet needs in patients with chronic liver disease: A mixed-method systematic review””
por: Grønkjær, Lea Ladegaard, et al.
Publicado: (2021)

In reply— Association of Renin-Angiotensin System Blockers with Outcomes in Patients With COVID-19
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Reply to: Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico
por: Vidal-Cevallos, Paulina, et al.
Publicado: (2021)

Reply to: “NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression – The debate continues”
por: Ji, Dong, et al.
Publicado: (2021)

Reply to “Consensus document on tracheotomy in patients with COVID-19”()
por: Martín Delgado, M.C., et al.
Publicado: (2021)

Reply to: Trajectories of vital signs in patients with Covid-19
por: Redfern, Oliver C., et al.
Publicado: (2021)

Reply to Consensus document on tracheotomy in patients with COVID 19()
por: Pérez Acosta, G., et al.
Publicado: (2021)

Reply: CPET for Long COVID-19
por: Mancini, Donna M., et al.
Publicado: (2022)

Reply to “The outbreak of COVID-19: An overview”
por: Wu, Yi-Chi, et al.
Publicado: (2020)

Reply to the syndemic of “COVID-19 and tuberculosis”
por: Patil, Rajashri A., et al.
Publicado: (2023)

Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020
por: Mallet, Vincent, et al.
Publicado: (2021)

Reply to: “Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients”
por: Rodríguez-Perálvarez, Manuel, et al.
Publicado: (2021)

Reply: molecular determinants of prognosis in oesophageal cancer patients treated with chemoradiation
por: Yoshikawa, R, et al.
Publicado: (2008)

Reply to: ‘No evidence for an increased liver uptake of SARS-CoV-2 in metabolic-associated fatty liver disease’
por: Ji, Dong, et al.
Publicado: (2020)

Reply to Letter: factors affecting COVID-19 outcomes in patients with congenital heart disease
por: Jeilani, Hammad, et al.
Publicado: (2021)

Reply to “Coronavirus Disease 19 (COVID-19): Implications for Clinical Dental Care”
por: Ather, Amber, et al.
Publicado: (2020)

Reply to :Aminotransferases disorders associated with venous thromboembolic events in patients infected with COVID-19
por: Hamadé, Amer, et al.
Publicado: (2021)

Reply: Value of tyrosinase RT–PCR in melanoma prognosis
por: Gogas, H
Publicado: (2003)

Reply: Iron chelation may harm patients with COVID-19
por: Abobaker, Anis
Publicado: (2020)

Reply to: Prognostic implications of vitamin D in patients with COVID-19
por: Hastie, Claire E., et al.
Publicado: (2020)

Reply to the Letter to the Editor “Pathogenesis of pneumoperitoneum in COVID-19 patients”()
por: Gemio del Rey, Ignacio Antonio, et al.
Publicado: (2021)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Reply to professionally responsible COVID-19 vaccination counseling
por: Chervenak, Frank A., et al.
Publicado: (2021)

Reply to “Pulmonary toxicity by oxygen and COVID-19”()
por: Belenguer-Muncharaz, A., et al.
Publicado: (2022)

Plasma hemoglobin in COVID-19: authors’ reply
por: Lancman, Guido, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_n2m2633bog97hno29pivivhrip